Homeostatic Model Assessment of Insulin Resistance
Glucose Metabolism marker
HOMA-IR
Homeostatic Model Assessment of Insulin Resistance
Calculated index of insulin resistance derived from fasting glucose and fasting insulin. Lower values indicate better insulin sensitivity. The most practical tool for detecting early GH/peptide-induced metabolic dysfunction.
PED Notes
Auto-calculated when both Fasting Glucose and Fasting Insulin are present in a blood test. Formula: (Glucose mmol/L x Insulin mIU/L) / 22.5. Lean, muscular athletes typically have lower baseline HOMA-IR (0.5-1.0) than sedentary adults. This means even 'normal' values (1.5-2.0) can represent a meaningful shift on GH or MK-677. Track the trend, not just the absolute number. A HOMA-IR that doubles from 0.8 to 1.6 over a GH cycle is a stronger signal than a single reading of 1.6 in isolation. GH, MK-677, and other GH-releasing peptides are the primary drivers of HOMA-IR elevation in this population. The index catches insulin resistance weeks before fasting glucose alone would flag a problem.
This index is auto-computed. It is not directly manageable.
Adjust the underlying metabolic state instead:
HOMA-IR below 1.0 (optimal for lean athletes):
- No intervention needed
- Continue current monitoring frequency
HOMA-IR 1.0-1.5 (watch zone):
- Acceptable on moderate GH/peptide doses
- Optimize diet: reduce refined carbs, increase fibre, time carbs around training
- Recheck in 3 months
HOMA-IR 1.5-2.5 (early insulin resistance):
- Consider reducing GH or MK-677 dose by 25-50%
- Berberine 500mg 2-3x daily with meals
- Chromium picolinate 200-1000 mcg/day
- Alpha-lipoic acid 300-600mg/day
- If trending upward despite supplements, discuss metformin with your physician
HOMA-IR above 2.5 (established insulin resistance):
- Stop or substantially reduce GH/peptide dose
- Metformin 500-1000mg/day (prescription)
- GLP-1 agonist if metformin is insufficient
- Recheck in 4-6 weeks after intervention
- Do not resume full dose until HOMA-IR returns below 1.5
Key principle: HOMA-IR is the earliest warning system. Fasting insulin rises before glucose does, and HOMA-IR captures this compensatory hyperinsulinemia before either glucose or HbA1c flags a problem. Act on the trend.
References:
- Matthews, D. R., Hosker, J. P., Rudenski, A. S., et al. (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7), 412-419. DOI: 10.1007/BF00280883
- Gonzalez-Cantero, J., Martin-Rodriguez, J. L., Gonzalez-Cantero, A., et al. (2014). Insulin resistance in lean and overweight non-diabetic Caucasian adults: study of its relationship with body composition, fat distribution and cardiovascular risk. PLOS ONE, 9(12), e115462. DOI: 10.1371/journal.pone.0115462
- Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004). Use and abuse of HOMA modeling. Diabetes Care, 27(6), 1487-1495. DOI: 10.2337/diacare.27.6.1487
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range